💊FDA PHARMA today

By FDA, Pharmaceutical

💊FDA PHARMA today

Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease | BMS Newsroom

https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-receives-fda-approval-opdivo-nivolumab-ad

More from tokioX :

  1. 💊FDA PHARMA TODAY
  2. 💊FDA PHARMA today
  3. 💊FDA PHARMA today
  4. 💊FDA PHARMA today
  5. 💊Pharma – News Releases
  6. 💊Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma (RCC)
  7. 💊Notice Regarding Implementation of New Drug Discovery Program “JOINUS” Using Drug Repositioning Compound Libraries by Astellas Pharma, Mitsubishi Tanabe Pharma and Daiichi Sankyo